CF
BPMC

Corebridge Financial’s Blueprint Medicines BPMC Stock Holding History

Corebridge Financial’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,151
Closed -$2.76M – 402
2025
Q1 		$2.76M Sell
31,151
-462
-1% -$45.1K 0.02% 875
2024
Q4 		$2.76M Sell
31,613
-2,006
-6% -$184K 0.01% 905
2024
Q3 		$3.11M Sell
33,619
-207
-0.6% -$20.6K 0.02% 887
2024
Q2 		$3.65M Buy
+33,826
New +$3.39M 0.02% 812

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Corebridge Financial's BPMC Position: Q2 2025 in Review

Corebridge Financial sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 31,151 shares — an estimated $2.76M sold.

Corebridge Financial first reported a position in BPMC in Q2 2024 and held it in 4 quarters. The position peaked at $3.65M in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Corebridge Financial reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 31,151 Blueprint Medicines shares in Q2 2025, an estimated $2.76M.
  • Corebridge Financial first reported a position in Blueprint Medicines in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Blueprint Medicines position peaked at $3.65M in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.